JP2008509086A5 - - Google Patents

Download PDF

Info

Publication number
JP2008509086A5
JP2008509086A5 JP2007515288A JP2007515288A JP2008509086A5 JP 2008509086 A5 JP2008509086 A5 JP 2008509086A5 JP 2007515288 A JP2007515288 A JP 2007515288A JP 2007515288 A JP2007515288 A JP 2007515288A JP 2008509086 A5 JP2008509086 A5 JP 2008509086A5
Authority
JP
Japan
Prior art keywords
seq
antibody
ligand
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007515288A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008509086A (ja
JP4890449B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/018322 external-priority patent/WO2005116077A2/en
Publication of JP2008509086A publication Critical patent/JP2008509086A/ja
Publication of JP2008509086A5 publication Critical patent/JP2008509086A5/ja
Application granted granted Critical
Publication of JP4890449B2 publication Critical patent/JP4890449B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007515288A 2004-05-25 2005-05-25 下流uPAR相互作用を阻害するウロキナーゼ型プラスミノーゲン活性化因子(uPA)とそのレセプター(uPAR)との複合体に結合するリガンド:診断または治療における同定および使用 Expired - Lifetime JP4890449B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57389604P 2004-05-25 2004-05-25
US60/573,896 2004-05-25
PCT/US2005/018322 WO2005116077A2 (en) 2004-05-25 2005-05-25 LIGANDS BINDING THE COMPLEX OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (uPA) AND ITS RECEPTOR (uPAR) THAT INHIBIT DOWNSTREAM uPAR INTERACTIONS: IDENTIFICATION AND USE IN DIAGNOSIS OR THERAPY

Publications (3)

Publication Number Publication Date
JP2008509086A JP2008509086A (ja) 2008-03-27
JP2008509086A5 true JP2008509086A5 (https=) 2008-07-10
JP4890449B2 JP4890449B2 (ja) 2012-03-07

Family

ID=35451457

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007515288A Expired - Lifetime JP4890449B2 (ja) 2004-05-25 2005-05-25 下流uPAR相互作用を阻害するウロキナーゼ型プラスミノーゲン活性化因子(uPA)とそのレセプター(uPAR)との複合体に結合するリガンド:診断または治療における同定および使用

Country Status (16)

Country Link
US (1) US8101726B2 (https=)
EP (1) EP1765397B1 (https=)
JP (1) JP4890449B2 (https=)
KR (1) KR20070047246A (https=)
CN (1) CN101022830A (https=)
AU (1) AU2005248400A1 (https=)
CA (1) CA2568428C (https=)
DK (1) DK1765397T3 (https=)
ES (1) ES2398221T3 (https=)
IL (1) IL179565A0 (https=)
MX (1) MXPA06013709A (https=)
PL (1) PL1765397T3 (https=)
PT (1) PT1765397E (https=)
RU (1) RU2006145905A (https=)
WO (1) WO2005116077A2 (https=)
ZA (1) ZA200610578B (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8343489B2 (en) * 2006-03-21 2013-01-01 Weaver David T Methods for humanizing antibodies and humanized antibodies made thereby
CN1919874B (zh) * 2006-09-18 2010-09-08 中国人民解放军军事医学科学院生物工程研究所 一种抗尿激酶型纤溶酶激活剂受体的抗体样分子ATF-Fc融合蛋白及其用途
DK2117571T3 (en) * 2006-12-08 2017-05-08 Monopar Therapeutics Inc Urokinase-type plasminogen activator receptor epitope
US8815519B2 (en) * 2006-12-22 2014-08-26 Hvidovre Hospital Method for predicting cancer and other diseases
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
ES2457822T3 (es) 2007-11-08 2014-04-29 The General Hospital Corporation Procedimientos y composiciones de tratamiento de enfermedades proteinúricas
CA2779958A1 (en) 2008-11-06 2010-05-14 University Of Miami Role of soluble upar in the pathogenesis of proteinuric kidney disease
CN102597775A (zh) 2009-09-25 2012-07-18 佐马技术有限公司 筛选方法
JP2014502965A (ja) 2010-12-22 2014-02-06 イフォム・フォンダツィオーネ・インスティトゥオ・フィルチ・ディ・オンコロジア・モレコラーレ uPARアンタゴニストおよびその使用
DK3252076T3 (da) 2011-01-14 2019-12-02 Univ California Diagnostisk anvendelse af antistoffer mod ror-1-protein
US20130344074A1 (en) 2011-03-16 2013-12-26 Sanofi Uses of a dual v region antibody-like protein
JP6055464B2 (ja) 2011-05-09 2016-12-27 ザ ユニバーシティー オブ マイアミ 循環血中の可溶性ウロキナーゼ受容体の低減
WO2013020898A1 (en) 2011-08-05 2013-02-14 Ifom Fondazione Istituto Firc Di Oncologia Molecolare Constitutively active upar variants and their use for the generation and isolation of inhibitory antibodies
CN110201144B (zh) * 2013-03-15 2024-01-02 得克萨斯州大学系统董事会 用Nutlin-3a和肽抑制肺纤维化
CN105368859B (zh) * 2015-11-25 2019-10-18 王任直 一种嵌合抗原受体hCD87-CAR及载有hCD87-CAR基因结构的慢病毒及质粒及其应用
US10959062B1 (en) 2018-04-19 2021-03-23 Tango Tango, Inc. System and method for push-to-talk over cellular integration with software defined radio
US10681506B1 (en) 2018-04-19 2020-06-09 Tango Tango, Inc. System and method for push-to-talk over cellular integration with software defined radio
AU2019339260B2 (en) 2018-09-10 2025-06-26 Rein Therapeutics, Inc. Modified peptide fragments of Cav-1 protein and the use thereof in the treatment of fibrosis
WO2020069498A1 (en) 2018-09-28 2020-04-02 Jochen Reiser Supar and prediction and treatment of acute kidney injury
US20230220112A1 (en) * 2019-10-28 2023-07-13 Monash University Antibodies for binding plasmin
CA3182769A1 (en) * 2020-06-15 2021-12-23 Andrew P. Mazar Precision radioimmunotherapeutic targeting of the urokinase plasminogen activator receptor (upar) for treatment of severe covid-19 disease
IL306074A (en) * 2021-03-24 2023-11-01 Alkermes Inc UPAR antibodies and fusion proteins with them
JP2024520180A (ja) * 2021-05-21 2024-05-21 ノーススター メディカル テクノロジーズ リミテッド ライアビリティ カンパニー ウロキナーゼプラスミノーゲンアクチベーター受容体標的放射性医薬品
AU2022287975A1 (en) * 2021-06-11 2023-12-14 Memorial Hospital For Cancer And Allied Diseases Antigen recognizing receptors targeting upar and uses thereof
CA3246325A1 (en) * 2022-03-24 2023-09-28 The United States Government As Represented By The Department Of Veterans Affairs Urokinase-type plasminogen activator receptor-binding peptides and methods of use
EP4610269A1 (en) 2024-02-29 2025-09-03 3B Pharmaceuticals GmbH Urokinase plasminogen activator surface receptor (upar) ligands for diagnostic or therapeutic use
WO2025207781A1 (en) 2024-03-26 2025-10-02 Monopar Therapeutics Inc. Antibody radioisotope constructs
WO2026019458A1 (en) 2024-07-19 2026-01-22 Monopar Therpeutics, Inc Squaramide bi-functional chelators and associated radiopharmaceuticals and methods of use
CN121248786A (zh) * 2025-12-08 2026-01-02 上海宏成药业有限公司 抗尿激酶纤溶酶原激活物受体抗体及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532132A (en) * 1993-09-28 1996-07-02 President And Fellows Of Harvard University Method for regulating formation of a complex of plasminogen activator, its receptor and inhibitor
DE10117381A1 (de) * 2001-04-06 2002-10-10 Wilex Biotechnology Gmbh Herstellung polyklonaler, monospezifischer Antikörper gegen die uPAR-Varianten del4, del5 und del4+5 sowie deren Verwendung für diagnostische und therapeutische Zwecke
US20030219837A1 (en) * 2002-03-18 2003-11-27 Cress Anne E. Integrin ligand
DK2117571T3 (en) * 2006-12-08 2017-05-08 Monopar Therapeutics Inc Urokinase-type plasminogen activator receptor epitope

Similar Documents

Publication Publication Date Title
JP2008509086A5 (https=)
JP7165217B2 (ja) 抗pdl1抗体、活性化可能抗pdl1抗体、およびその使用方法
JP7014706B2 (ja) 抗pd-1抗体、活性化可能抗pd-1抗体、およびその使用方法
RU2006145905A (ru) Лиганды, связывающие комплекс активатора плазминогена урокиназного типа (upa) и его рецептора (upar), которые ингибируют последующие взаимодействия upar: идентификация и использование в диагностике или терапии
IL290412B2 (en) New monoclonal antibodies to cd47 and their uses
JP2009517057A5 (https=)
JP2019534034A5 (https=)
US20160355599A1 (en) Anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereof
ES2610225T3 (es) Péptidos y epítopos anti P2X7
Behar et al. Llama single‐domain antibodies directed against nonconventional epitopes of tumor‐associated carcinoembryonic antigen absent from nonspecific cross‐reacting antigen
JP2005538701A5 (https=)
EP3762420A1 (en) Activatable cd147 antibodies and methods of making and use thereof
JP2013506428A5 (https=)
US8735554B2 (en) Reagents, methods, and systems for detecting methicillin-resistant Staphylococcus
RU2008146922A (ru) Антитела, связывающиеся с внеклеточным доменом тирозинкиназного рецептора (alk)
JP2010523096A5 (https=)
JP2010501164A5 (https=)
JP2013531655A5 (https=)
EP3085387A1 (en) Sparc binding antibodies and uses thereof
JP2005535562A5 (https=)
RU2016129526A (ru) Антитело, выделенная нуклеиновая кислота, выделенный паратоп антитела, выделенный конформационный эпитоп, связывающая молекула, иммуноген, фармацевтический и диагностический препараты, лекарственная форма вакцины, способ лечения больного, подверженного риску или страдающего от инфекции Staphylococcus aureus, способ диагностики обнаружения инфекций Staphylococcus aureus и способ скрининга или анализа для определения связующего
EP2984108B1 (en) Anti-s100a7 antibodies for the treatment and diagnosis of cancer
JP2009544574A5 (https=)
CN103201291B (zh) 抗单链iv型胶原多肽抗体和包含其的用于诊断、预防或治疗肿瘤的药物或药剂
CN115873114A (zh) Ctla-4结合分子及其应用